Enhanced Humoral Responses Induced by Targeting of Antigen to Murine Dendritic Cells

Scandinavian Journal of Immunology

Volumn 82, Issue 6, 2015, Pages 515-522

  Pugholm, L H ^a,b   Petersen, L R ^b   Sondergaard E K L ^a   Varming, K ^a   Agger, R ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD205 ANTIGEN; CD36 ANTIGEN; CLEC9A PROTEIN; DECTIN 1; DECTIN 2; GLYCOPROTEIN P 15095; MONOCLONAL ANTIBODY; SIGLEC H; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL; UNCLASSIFIED DRUG; MEMBRANE ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMORAL IMMUNITY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; C57BL MOUSE; DRUG DELIVERY SYSTEM; IMMUNIZATION; IMMUNOLOGY; PROCEDURES; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS; ANTIGENS, SURFACE; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNITY, HUMORAL; IMMUNIZATION; MICE; MICE, INBRED C57BL; RATS;

EID: 84945273111     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12387     Document Type: Article

References (49)

1. Tacken PJ, de Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7:790-802.
2. Caminschi I, Maraskovsky E, Heath WR. Targeting dendritic cells in vivo for cancer therapy. Front Immunol 2012;3:13.
3. Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol 2011;23:12-20.
4. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265-77.
5. Cohn L, Delamarre L. Dendritic cell-targeted vaccines. Front Immunol 2014;5:1-11.
6. Wimmers F, Schreibelt G, Sköld AE, Figdor CG, De Vries IJM. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol 2014;5:165.
7. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70.
8. Corbett AJ, Caminschi I, McKenzie BS et al. Antigen delivery via two molecules on the CD8- dendritic cell subset induces humoral immunity in the absence of conventional "danger". Eur J Immunol 2005;35:2815-25.
9. Cheong C, Choi J-H, Vitale L et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 2010;116:3828-38.
10. Idoyaga J, Lubkin A, Fiorese C et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci USA 2011;108:2384-9.
11. Bonifaz LC, Bonnyay DP, Charalambous A et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004;199:815-24.
12. Caminschi I, Proietto AI, Ahmet F et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 2008;112:3264-73.
13. Lahoud MH, Ahmet F, Kitsoulis S et al. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. J Immunol 2011;187:842-50.
14. Mahnke K, Qian Y, Fondel S et al. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 2005;65:7007-12.
15. Castro FV, Tutt AL, White AL et al. CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur J Immunol 2008;38:2263-73.
16. Bilsland C, Diamond M, Springer T. The leukocyte integrin p150, 95 (CD11c/CD18) as a receptor for iC3b. Activation by a heterologous beta subunit and localization of a ligand recognition site to the I domain. J Immunol 1994;152:4582-9.
17. Stacker S, Springer T. Leukocyte integrin P150, 95 (CD11c/CD18) functions as an adhesion molecule binding to a counter-receptor on stimulated endothelium. J Immunol 1991;146:648-55.
18. Frick C, Odermatt A, Zen K et al. Interaction of ICAM-1 with beta 2-integrin CD11c/CD18: characterization of a peptide ligand that mimics a putative binding site on domain D4 of ICAM-1. Eur J Immunol 2005;35:3610-21.
19. Martin C, Chevrot M, Poirier H et al. CD36 as a lipid sensor. Physiol Behav 2011;105:36-42.
20. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009;2:re3.
21. Albert BML, Pearce SFA, Francisco LM et al. Immature dendritic cells phagocytose apoptotic cells via alphaVbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188:1359-68.
22. Cambi A, Figdor CG. Dual function of C-type lectin-like receptors in the immune system. Curr Opin Cell Biol 2003;15:539-46.
23. Geijtenbeek T, Gringhuis S. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009;Jul; 9:465-79.
24. Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and langerhans cells. Nat Rev Immunol 2002;2:77-84.
25. Shrimpton RE, Butler M, Morel A et al. CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self. Mol Immunol 2009;46:1229-39.
26. Drummond RA, Brown GD. Signalling C-type lectins in antimicrobial immunity. PLoS Pathog 2013;9:e1003417.
27. Killick KE, Ní Cheallaigh C, O'Farrelly C et al. Receptor-mediated recognition of mycobacterial pathogens. Cell Microbiol 2013;15:1484-95.
28. Sancho D, Mourao-Sa D, Joffre OP et al. Tumor therapy in mice via antigen targeting to a novel. DC-restricted C-type lectin. J Clin Invest 2008;118:2098-110.
29. Zhang J-G, Czabotar PE, Policheni AN et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity 2012;36:646-57.
30. Joffre OP, Sancho D, Zelenay S, Keller AM, Reis e Sousa C. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-I/CLEC9A. Eur J Immunol 2010;40:1255-65.
31. Watarai H, Sekine E, Inoue S et al. PDC-TREM, a plasmacytoid dendritic cell-specific receptor, is responsible for augmented production of type I interferon. Proc Natl Acad Sci USA 2008;105:2993-8.
32. Swiecki M, Wang Y, Vermi W et al. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med 2011;208:2367-74.
33. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 2009;21:38-46.
34. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007;7:255-66.
35. Blasius AL, Cella M, Maldonado J, Takai T, Colonna M. Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 2006;107:2474-6.
36. Zhang J, Raper A, Sugita N et al. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 2006;107:3600-8.
37. Blasius AL, Colonna M. Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trends Immunol 2006;27:255-60.
38. Carter RW, Thompson C, Reid DM, Wong SYC, Tough DF. Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol 2006;177:2276-84.
39. Wang B, Zaidi N, He L-Z et al. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 2012;14:R39.
40. Wang H, Griffiths MN, Burton DR, Ghazal P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA 2000;97:847-52.
41. Boscardin SB, Hafalla JC, Masilamani RF et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 2006;203:599-606.
42. Wei H, Wang S, Zhang D et al. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res 2009;15:4612-21.
43. Salio M, Palmowski MJ, Atzberger A, Hermans IF, Cerundolo V. CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. J Exp Med 2004;199:567-79.
44. Schlecht G, Garcia S, Escriou N et al. Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood 2004;104:1808-15.
45. Shortman K, Lahoud MH, Caminschi I. Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med 2009;41:61-6.
46. Caminschi I, Lahoud MH, Shortman K. Enhancing immune responses by targeting antigen to DC. Eur J Immunol 2009;39:931-8.
47. Li J, Ahmet F, Sullivan LC et al. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol 2015;mar; 45:854-854. 1-11.
48. Tacken PJ, Ginter W, Berod L et al. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 2011;118:4111-9.
49. Dhodapkar MV, Sznol M, Zhao B et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014;6:232ra51.